Abbott wins EU approval for smallest version of glucose monitoring device
[BENGALURU] Abbott Laboratories' said on Monday it had received clearance to market the smallest version of its fastest-growing low-cost diabetes monitoring product in the European Union.
FreeStyle Libre 3, which received the European CE Mark, is a more discreet sensor and will be priced the same as previous versions of the device, the company said.
The earlier version, Libre 2, is priced at US$54, while a handheld reader, used to scan the sensor, is available for a one-time cost of US$70.
FreeStyle Libre 3 is a continuous glucose monitoring device that allows diabetics to track their blood sugar levels without multiple daily finger sticks.
Patients using the new version will also be able to receive glucose readings automatically on their smartphones through the FreeStyle Libre 3 mobile app.
The Libre 3 sensor, like other versions, is worn at the back of the upper arm for 14 days.
GET BT IN YOUR INBOX DAILY
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
In April, the company said worldwide sales of Freestyle Libre devices rose 59.3 per cent to US$600 million in the first quarter of 2020.
REUTERS
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Sheng Siong Q1 net profit up 9.3% on higher revenue
Nestle sales growth sputters on US slump, vitamin snags
Hermes Q1 sales jump 17% on strong China demand
Cordlife’s independent auditor to retire after issuing disclaimer of opinion on FY2023 financials
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Cordlife customers push for legal action